Research programme: Cannabidiol therapeutics - Phytecs

Drug Profile

Research programme: Cannabidiol therapeutics - Phytecs

Alternative Names: 4'-F-CBD; Fluorinated cannabidiol; HUF 101; HUF 102; HUF 103

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Universidade Federal do Rio Grande do Sul; University of Sao Paulo; Yissum Research Development Company
  • Class Cannabinoids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders; Obsessive-compulsive disorders; Psychotic disorders

Most Recent Events

  • 22 Feb 2017 Phytec and Yissum Research Development agree to co-develop Cannabidiol therapeutics
  • 09 Aug 2016 Preclinical trials in Anxiety disorders in USA (unspecified route)
  • 09 Aug 2016 Preclinical trials in Depressive disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top